Poolbeg Pharma PLC Directorate Change (1292V)
30 Noviembre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 1292V
Poolbeg Pharma PLC
30 November 2023
Poolbeg Pharma plc
Directorate Change
30 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a biopharmaceutical company focussed
on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces a
change to its Board of Directors.
Patrick Ashe, Independent Non-Executive Director, will step down
from the Board at the end of November. Patrick played a significant
role in guiding the Company through its initial phase of
development. Eddie Gibson, Non-Executive Director will replace
Patrick as Chair of the Audit & Risk Committee and Prof Brendan
Buckley, Non-Executive Director will become Chair of the
Remuneration Committee.
Cathal Friel, Chairman of Poolbeg Pharma, commented: "We would
like to thank Patrick for his contribution since joining at the
IPO, where his knowledge and experience of growing biopharma
companies has been of considerable value. Patrick joined the
Company as part of its IPO and steps down from the Board at a time
when Poolbeg is on an upward trajectory with a robust pipeline of
high value programmes, and at a particularly exciting juncture
following the recent appointment of three key former Amryt Pharma
plc leadership members to the Poolbeg team with the view to
replicating the success they had with Amryt. With a strong
financial position, excellent clinical results achieved and
productive partnering discussions ongoing, the Company is well
positioned to generate significant shareholder value."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd
(Nominated Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint
Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Vici Rabbetts, Elena poolbeg@optimumcomms.com
Bates
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to fund the development of its robust pipeline of innovative
products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history
of delivering significant shareholder value. The team has been
strengthened by the appointment of three former members of the
Amryt Pharma plc leadership team, with the intention of repeating
Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets
across cancer immunotherapies, severe influenza, and metabolic
conditions such as obesity with the development of an oral GLP-1R
agonist. It uses a cost-effective development philosophy to
generate high quality human data to support partnering and further
development. Its AI-led programmes analyse unique data from human
challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial
appeal.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABIBDBIBDDGXC
(END) Dow Jones Newswires
November 30, 2023 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024